Narek Shaverdian, MD
Lung Cancer; Brain Cancer and Other Central Nervous System Tumors; Spine Tumors; Bone Tumors; Image-Guided Radiation Therapy (IGRT); Intensity-Modulated Radiation Therapy (IMRT); Streotactic Radiosurgery (SRS); Stereotactic Body Radiation Therapy (SBRT); Stereotactic Ablative Radiotherapy (SABR)
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Shaverdian accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, University of Wisconsin
Preliminary Medicine - University of Washington; Radiation Oncology - University of California Los Angeles
I was drawn to being a cancer doctor and researcher because, as with so many families, mine too has been impacted by this disease. I strive to provide the same personalized care that I would hope someone in my own family would receive.
When I first meet patients, I help them understand the role radiation therapy can play in their specific treatment plan. Often patients may have new questions or challenges after we meet, so I want my patients to know that I strive to be completely accessible. I am committed to working through all the steps with them to ensure that they have the best treatment experience and best outcome. It is a great privilege to get to know my patients and their families and work to provide cutting-edge, personalized care.
There have been great advances in radiation oncology. These enable us to control and defeat cancer with minimal side effects. At Memorial Sloan Kettering, we take advantage of the most sophisticated image guidance technology to deliver radiation with great precision. We have developed ways to treat some people with fewer sessions by using higher, tightly focused doses. We are also investigating ways to combine radiation with certain drugs to get even better results.
In addition to my clinical practice, I conduct research on the interaction between radiation therapy and a person’s own immune system. This is a growing area of research in which we are looking for ways to improve the effectiveness of radiation therapy by giving immunotherapy drugs. I am also interested in finding ways we can better understand the concerns and perspectives of our patients as they undergo treatment.
I also want patients to know that the care I provide is complemented by a large team of experts in oncology, surgery, radiology, and pathology, all who work closely with each other. I hope my patients always leave my office feeling informed, comfortable, and confident in their treatment plan.
It is a great privilege to get to know my patients and their families and work to provide cutting-edge, personalized care.
Awards and Honors
- Radiological Society of North America (RSNA) Roentgen Research Award (2018)
- American Society for Radiation Oncology (ASTRO) Basic/Translational Science Abstract Award (2017)
- American Society for Clinical Oncology (ASCO) Merit Award (2017)
- American Medical Association (AMA) Foundation Seed Grant (2017)
- American College of Radiation Oncology (ACRO) Grant (2015)
- Alpha Omega Alpha Honor Medical Society (2013)
- Clinical Trials Investigated by Dr. Shaverdian
- A Phase II Study of Canakinumab with Chemotherapy, Radiation Therapy, and Durvalumab in People with Lung Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Shaverdian N, Wang X, Hegde JV, Aledia C, Weidhaas JB, Steinberg ML, McCloskey SA. The patient’s perspective on breast radiation therapy: Initial fears and expectations versus reality. Cancer. 2018 Apr 15;124(8):1673-1681
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncology. 2017 Jul;18(7):895-903.
Shaverdian N, Veruttipong D, Wang PC, Kishan AU, Demanes DJ, McCloskey S, Kupelian P, Steinberg ML, King CR. Exploring value from the patient’s perspective between modern radiation therapy modalities for localized prostate cancer. International Journal of Radiation Oncology, Biology, and Physics. 2017 Mar 1;97(3):516-525.
Shaverdian N, Veruttipong D, Wang J, Kupelian P, Steinberg M, Lee P. Pretreatment anemia portends poor survival and nonlocal disease progression in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Journal of Thoracic Oncology. 2016 Aug;11(8):1319-25.
Shaverdian N, Wang PC, Steinberg M, Lee P. The patient’s perspective on stereotactic body radiation therapy vs. surgery for the treatment of early stage non-small cell lung cancer. Lung Cancer. 2015 Nov;90(2):230-3.
Visit PubMed for a full listing of Dr. Shaverdian’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Narek Shaverdian discloses the following relationships and financial interests:
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.